A novel SPECT/CT imaging probe, 99mTc-sum IL-2, targets IL-2Rβ/IL-2Rγ receptors on tumor-infiltrating T cells, showing potential in predicting immune responses to anti-PD-L1 therapy and tracking adoptively transferred (ACT) T cells (57). This evidence concerns the gene CD274 and neoplasm.